⚕ GalenOps field
←

SITE010-0101

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-06-27

AEs
8
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 47); relationship: not assessed

severe assessed

Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 121); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-05 (study day 122); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 134); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-25 (study day 172); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-18 (study day 196); relationship: N

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 261); relationship: N

moderate assessed

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-04-04 (study day 272); relationship: not assessed

Data queries

No data queries.